Ambroxol as a Disease-modifying Treatment in GBA-PD
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associat ...
Parkinson Disease;GBA Gene Mutation
Drug: Ambroxol Hydrochloride;Drug: Placebo
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
University of Campania Luigi Vanvitelli;IRCCS National Neurological Institute C. Mondino Foundation
A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynamic (biochemical and physiological effects of drugs). The effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease. A Pilot Study to Evaluate the Safety, Tolerability (any side effects of the drug) and Pharmacodynami ...
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PD A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerabili ...
Parkinson disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: AMBROSAN 60mg Tablets Product Name: Ambroxol INN or Proposed INN: Ambroxol hydrochloride
Joint Research Office
NULL
Not Recruiting
Female: yes Male: yes
20
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...